<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ880825-0029 </DOCNO><HL> Business Brief: Cetus Corp. </HL><SO> </SO><CO> CTUS </CO><IN> PHA </IN><TEXT>   Cetus Corp., Emeryville, Calif., said it received a patent covering an advanced form of its anticancer agent, interleukin-2.    The biotechnology concern said the latest patent covers PEG, or polyethylene glycol, IL-2. The agent involves attaching polymers to the IL-2 protein molecule to increase the time it remains active in the body and to improve solubility. Cetus holds more than a dozen patents on various forms of IL-2 and related technology. </TEXT></DOC>